Indivior Pharmaceuticals, Inc. (E7P)
FSX
31.00
-0.40 (-1.27%)
Real-time Data
06:00 AM
Day's Range
31.0031.00
52 wk Range
17.5036.60
Financial Statements - E7P - Indivior Pharmaceuticals, Inc.
Revenue
1.23B▲ 4.3%
Net Income
210.00M▲ 6900.0%Net Margin 16.9%
EBITDA
307.00M▲ 9.6%
Free Cash Flow
-94.00M▼ 1980.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 1.23B | 1.18B |
| Cost of Goods | 246M | 231M |
| Gross Profit | 993M | 957M |
 Operating Expense | - | - |
| Operating Income | 265M | 228M |
| Non-Operating Interest | - | - |
| Other Income Expense | -3M | - |
| Pre Tax Income | 239M | 14M |
| Income Tax | 29M | 11M |
| Net Income | 210M | 3M |
| EPS Basic | 1.68 | -0.36 |
| EPS Diluted | 1.64 | -0.36 |
| Basic Shares Outstanding | 125M | 132.30M |
| Diluted Shares Outstanding | 125M | 132.30M |
| Ebit | 284M | 55M |
| Ebitda | 307M | 280M |
| Net Income Continuous Operations | 210M | 2M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
